RSV vaccine

The U.S. Food and Drug Administration (FDA) expanded approval of Moderna Inc.’s (NASDAQ:MRNA) respiratory syncytial virus vaccine to adults aged 18-59 at increased risk for disease. What Happened: The FDA on Thursday approved broader use of Moderna’s mRESVIA vaccine for younger at-risk...

Novavax, Inc. (NASDAQ: NVAX)’s massive 84.5 percent Friday blowup was certainly a shock for biotech investors. However, in an industry where a company’s fate can lie primarily in a single drug candidate, blowups like Novavax’s happen all too frequently. Here’s a look at five...

It’s hard to find a silver lining following news that sends a stock crashing 84.5 percent in one day. However, following devastating news that the Phase III RESOLVE trial of its RSV vaccine failed to deliver the desired results, Novavax, Inc. (NASDAQ: NVAX) shareholders are looking for any...